TURN-COVID Biobank: The Dutch cohort study for the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2

TURN-COVID Biobank: The Dutch cohort study for the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2 - TURN-COVID

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52215

Enrollment

1000

Registered

2021-11-15

Start date

2021-12-14

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 SARS-CoV-2

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - All patients that are treated with neutralizing SARS-CoV-2 antibodies and other antivirals against or as prevention of SARS-CoV-2 as standard of care. - Patients have to be aged >= 18 y.

Exclusion criteria

Exclusion criteria: - No informed consent is provided by the patient - Patients not suitable to fulfil study procedures

Design outcomes

Primary

Measure	Time frame
- A. What are the SARS-CoV-2 viral load kinetics during and after treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2? - B. What is the risk of SARS-CoV-2 infection after prophylactic use of monoclonal antibodies or other antiviral agents? - C. Do viral variants, spike mutations and immune escape occur during treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2? - D. What are the viral antibody and inflammatory response kinetics during and after treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2?	—

Measure

Time frame

- A. What are the SARS-CoV-2 viral load kinetics during and after treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2? - B. What is the risk of SARS-CoV-2 infection after prophylactic use of monoclonal antibodies or other antiviral agents? - C. Do viral variants, spike mutations and immune escape occur during treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2? - D. What are the viral antibody and inflammatory response kinetics during and after treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2?

—

Secondary

Measure	Time frame
- Not-applicable	—

Countries

Netherlands

Outcome results